Implementation of a Drug Screening Platform to Target Gch1 Expression in Injured Mouse Dorsal Root Ganglion Neurons

Shane J F Cronin; Lance S Davidow; Anthony C Arvanites; Lee L Rubin; Josef M Penninger; Clifford J Woolf

doi:10.21769/BioProtoc.4666

Implementation of a Drug Screening Platform to Target Gch1 Expression in Injured Mouse Dorsal Root Ganglion Neurons

Bio Protoc. 2023 May 5;13(9):e4666. doi: 10.21769/BioProtoc.4666.

Authors

Shane J F Cronin^{1

2}, Lance S Davidow^{3

4}, Anthony C Arvanites^{3

4}, Lee L Rubin^{3

4}, Josef M Penninger⁵, Clifford J Woolf^{1

2}

Affiliations

¹ FM Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA 02115, USA.
² Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA.
³ Harvard University Department of Stem Cell and Regenerative Biology, 7 Divinity Ave, Cambridge, MA, 02138, USA.
⁴ Harvard Stem Cell Institute, Harvard University, Cambridge MA 02138, USA.
⁵ Institute of Molecular Biotechnology Austria (IMBA), Dr. Bohrgasse 3, A-1030 Vienna, Austria.

Abstract

Management of neuropathic pain is notoriously difficult; current analgesics, including anti-inflammatory- and opioid-based medications, are generally ineffective and can pose serious side effects. There is a need to uncover non-addictive and safe analgesics to combat neuropathic pain. Here, we describe the setup of a phenotypic screen whereby the expression of an algesic gene,Gch1, is targeted. GCH1 is the rate-limiting enzyme in the de novo synthesis of tetrahydrobiopterin (BH4), a metabolite linked to neuropathic pain in both animal models and in human chronic pain sufferers.Gch1is induced in sensory neurons after nerve injury and its upregulation is responsible for increased BH4 levels. GCH1 protein has proven to be a difficult enzyme to pharmacologically target with small molecule inhibition. Thus, by establishing a platform to monitor and target inducedGch1 expression in individual injured dorsal root ganglion (DRG) neurons in vitro, we can screen for compounds that regulate its expression levels. This approach also allows us to gain valuable biological insights into the pathways and signals regulating GCH1 and BH4 levels upon nerve injury. This protocol is compatible with any transgenic reporter system in which the expression of an algesic gene (or multiple genes) can be monitored fluorescently. Such an approach can be scaled up for high-throughput compound screening and is amenable to transgenic mice as well as human stem cell-derived sensory neurons. Graphical overview.

Keywords: BH4; DRG neurons; Drug screen; GCH1; Neuropathic pain.

Abstract

Grants and funding